Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/4550


Healthcare Review: Cancer - October 2002


Description: The Cancer Review brings you the latest news, expert analysis and research in the oncology industry. It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.Strategic insight into the future shape of cancer companies and marketsThe most significant cancer industry news compiled into one monthly updateExpert analysis into the implications of the month's important cancer industry eventsInsight into the future shape of the market for players at all levelsAll the month's cancer stories in headline and summary formOut of the dozens of topics covered in this month's review, the most important include:* Novartis's Gleevec was granted a priority review by the FDA for possible use as a first-line treatment for newly diagnosed patients with Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase, the earliest stage of the disease.* A US District Court jury found unanimously in favor of Genentech following the claims of Chiron's that Genentech had infringed a patent with its metastatic breast cancer drug, Herceptin.Not only keeps you updated about industry events - it also gives you opinion and insightDraws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest eventsProvides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues


Contents: Overview

Introduction


The Cancer Review brings you the latest news, expert analysis and research in the cancer industry. It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.


Scope



  • Strategic insight into the future shape of cancer companies and markets


  • The most significant cancer industry news compiled into one monthly update


  • Expert analysis into the implications of the month's important cancer industry events


  • Insight into the future shape of the market for players at all levels


  • All the month's cancer stories in headline and summary form



Report Highlights


Out of the dozens of topics covered in this month's review, the most important include:


* Novartis's Gleevec was granted a priority review by the FDA for possible use as a first-line treatment for newly diagnosed patients with Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase, the earliest stage of the disease.


* A US District Court jury found unanimously in favor of Genentech following the claims of Chiron's that Genentech had infringed a patent with their metastatic breast cancer drug, Herceptin.


Reasons to Purchase



  • Not only keeps you updated about industry events - it also gives you opinion and insight


  • Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events


  • Provides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues



R&D UPDATE: BREAST CANCER


The most significant news in breast cancer R&D, compiled into one monthly update.


R&D UPDATE: LUNG CANCER


The most significant news in lung cancer R&D, compiled into one monthly update.


R&D UPDATE: PROSTATE CANCER


The most significant news in prostate cancer R&D, compiled into one monthly update.


R&D UPDATE: COLORECTAL CANCER


The most significant news in colorectal cancer R&D, compiled into one monthly update.


R&D UPDATE: OTHER CANCERS


The most significant news in other cancers, compiled into one monthly update including:



  • Lymphoma and leukemia


  • Brain cancer


  • Ovarian cancer


  • Liver cancers



LATEST COMMENT


Expert analysis of the implications of the month's important industry events



  • Novartis: multiple roles for Gleevec


  • AstraZeneca: a nail in the coffin of EGFr inhibitor hopes


  • Novuspharma: lending a hand to Micromet


  • Chiron/Genentech: battling on despite Herceptin ruling



MARKET SNAPSHOTS


Insight into the future shape of the market for players at all levels



  • Tumors: breast most common in 2001


  • Malignant melanoma: incidence to hit 77,000 in 2010



NEWS HEADLINES - BREAST CANCER


All the month's breast cancer news stories in headline and summary form


NEWS HEADLINES - LUNG CANCER


All the month's lung cancer news stories in headline and summary form


NEWS HEADLINES - PROSTATE CANCER


All the month's prostate cancer news stories in headline and summary form


NEWS HEADLINES - COLORECTAL CANCER


All the month's colorectal cancer news stories in headline and summary form


NEWS HEADLINES - OTHER CANCERS


All the month's other cancer news stories in headline and summary form




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/4550

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 26/11/2009 05:27:29
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Healthcare Review: Cancer - October 2002
Web Address:
http://www.researchandmarkets.com/reports/4550
Office Code:
OC8HJNMPMSTQQ

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €107.00 + EUR€ 25.00 Shipping/Handling *
Electronic €67.00
* Shipping/Handling is only charged once per order.


Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 26/11/2009 05:27:29

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)